- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04103671
Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe NPDR
Micro-invasive Pars-plana Vitrectomy vs Panretinal Photocoagulation for Severe Non-Proliferative Diabetic Retinopathy A Randomized Clinical Trial
It is estimated that there are about 600 million diabetes mellitus (DM) patients all over the world until 2040,and almost 50% of whom have some degree of diabetic retinopathy (DR) at any given time. About 5% to 10% diabetic retinopathy would develop vision-threatening complications, including proliferative diabetic retinopathy (PDR), capillary non-perfusion, or macular edema. Data from the DRS suggest that given long enough duration of diabetes, approximately 60% of patients with DR will develop PDR, and without intervention, 75% nonproliferative diabetic retinopathy (NPDR) will development PDR within 1 year follow up, 45% will develop high-risk PDR, nearly half of PDR will experience profound visual loss. panretinal photocoagulation (PRP) only reduced 50% risk of sever visual loss and about 25% of the sNPDR patients who finished PRP need Pars-plana vitrectomy (PPV) in a 5 year follow up.
Vitreous have been proven to play an important role in the development of NPDR to PDR, which were the collection of vascular endothelial growth factor (VEGF) factors and the major component of proliferative lesion in the later stage of PDR.
Micro-invasive Pars-plana vitrectomy has been shown as a safe and effective method in the treatment of PDR, through removing the pathological vitreous, proliferative membrane and also the VEGF factors. However, whether or not Micro-invasive Pars-plana vitrectomy will be more effective than PRP to control the progression of NDPR remained unknown.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: tao li, Dr
- Phone Number: +8620 66683995
- Email: litao2@mail.sysu.edu.cn
Study Contact Backup
- Name: shida chen, Dr
- Phone Number: +8620 66610721
- Email: chenshd3@mail.sysu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Recruiting
- Zhongshan Ophthalmic Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged ≥18 years, male or female
- Type 1 or type 2 diabetes
Presence of severe NPDR according to the diagnosis of 4-2-1 rule,
One or more of the following, in the absence of PDR:
- More than 20 intraretinal hemorrhages in each of four quadrants
- Definite venous beading in two or more quadrants
- Prominent intraretinal microvascular abnormality (IRMA) in one or more quadrants
- Best corrected Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS) visual acuity letter score > 24 (approximate Snellen equivalent 20/320) on the day of randomization.
- Media clarity, pupillary dilation, and study participant cooperation sufficient to administer PRP and obtain adequate fundus photographs and optical coherence tomography (OCT).
- Able and willing to provide informed consent
Exclusion Criteria:
- Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant
- In the opinion of the investigator, A condition that would preclude participation in the study (e.g., unstable medical status including blood pressure, cardiovascular disease, and glycemic control).
- Participation in an investigational trial within 30 days of randomization that involved treatment with any drug that has not received regulatory approval for the indication being studied.
Blood pressure > 180/110 (systolic above 180 or diastolic above 110).
*If blood pressure is brought below 180/110 by anti-hypertensive treatment, individual can become eligible.
- Myocardial infarction, other acute cardiac event requiring hospitalization, stroke, transient ischemic attack, or treatment for acute congestive heart failure within 4 months prior to randomization
Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to randomization
* These drugs should not be used during the study
For women of child-bearing potential: pregnant or lactating or intending to become pregnant within the next 3 years.
* Women who are potential study participants should be questioned about the potential for pregnancy. Investigator judgment is used to determine when a pregnancy test is needed
- History of prior panretinal photocoagulation (prior PRP is defined as ≥100 burns outside of the posterior pole
- If macular edema is present, it is considered to be primarily due to a cause other than diabetic macular edema.
- An ocular condition is present (other than diabetic retinopathy) that, in the opinion of the investigator, might alter visual acuity during the course of the study (e.g., retinal vein or artery occlusion, uveitis or other ocular inflammatory disease, neovascular glaucoma, etc.).
- Substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more (i.e., cataract would be reducing acuity to 20/40 or worse if eye were otherwise normal).
- History of intravitreal anti-VEGF treatment at any time in the past 2 months
- History of corticosteroid treatment (intravitreal or peribulbar) at any time in the past 4 months.
- History of major ocular surgery (including vitrectomy, cataract extraction, scleral buckle, any intraocular surgery, etc.) within prior 4 months or anticipated within the next 6 months following randomization.
- History of laser capsulotomy performed within 2 months prior to randomization
- Aphakia.
- Uncontrolled glaucoma (in investigator's judgment).
- Exam evidence of severe external ocular infection, including conjunctivitis, chalazion, or substantial blepharitis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group A
Prompt panretinal photocoagulation
|
Study eyes that receive panretinal photocoagulation (prompt PRP eyes at baseline) should have 1200 to1600 burns with a spot size on the retina of approximately 500 microns given over 1 to 3 sittings and completed within 4 weeks of initiation
|
Experimental: Group B
Micro-invasive Pars-plana vitrectomy
|
Study eyes that receive standard 25G Pars-plana vitrectomy that remove all the vitreous, without laser or Silicone oil tamponade, but filled with perfusion fluid.
Surgery should be completed within 4 weeks after randomization.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
progression rate of severe non proliferative diabetic retinopathy
Time Frame: 12 months
|
the number of patients with severe non proliferative diabetic retinopathy progressed to proliferative diabetic retinopathy in each group from the baseline to 12 months
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
the change of best corrected visual acuity
Time Frame: 12 months
|
The mean change in best corrected visual acuity in each group from baseline to 12 months
|
12 months
|
the rate of re-treatment
Time Frame: 12 months
|
The number of patients who need re-treatment including supplement laser or vitrectomy from baseline to 12 months
|
12 months
|
The occurrence of diabetic macular edema
Time Frame: 12 months
|
The occurrence number of diabetic macular edema in each group from baseline to 12 months
|
12 months
|
The change of central retinal thickness
Time Frame: 12 months
|
the change of central retinal thickness from baseline to 12 months
|
12 months
|
The change of visual field
Time Frame: 12 months
|
the change of visual field from baseline to 12 months
|
12 months
|
The occurrence of cataract
Time Frame: 12 months
|
the occurrence of cataract from baseline to 12 months
|
12 months
|
The change of quality of life
Time Frame: 12 months
|
the change of quality of life as assessed by questionnaire at 12 months
|
12 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019KYPJ108
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Proliferative Diabetic Retinopathy
-
University of CataniaUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyItaly
-
Asociación para Evitar la Ceguera en MéxicoUnknownProliferative Diabetic Retinopathy | Non Proliferative Diabetic RetinopathyMexico
-
Valo Health, Inc.RecruitingProliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
Asociación para Evitar la Ceguera en MéxicoUnknownNon Proliferative Diabetic Retinopathy. | Proliferative Diabetic Retinopathy.Mexico
-
Ocuphire Pharma, Inc.CompletedDiabetic Retinopathy | Diabetic Macular Edema | NPDR - Non Proliferative Diabetic Retinopathy | PDR - Proliferative Diabetic RetinopathyUnited States
-
King Khaled Eye Specialist HospitalCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathySaudi Arabia
-
Retina Macula InstituteAllerganCompletedDiabetic Macular Edema | Proliferative Diabetic Retinopathy | Non-proliferative Diabetic RetinopathyUnited States
-
Fengmei LianGuang'anmen Hospital of China Academy of Chinese Medical Sciences; Hubei Hospital... and other collaboratorsUnknownType2 Diabetes | Diabetic Non-proliferative Retinopathy
-
Hanlim Pharm. Co., Ltd.RecruitingNon Proliferative Diabetic RetinopathyKorea, Republic of
-
Greater Houston Retina ResearchGenentech, Inc.Active, not recruitingNon-Proliferative Diabetic RetinopathyUnited States
Clinical Trials on Prompt panretinal photocoagulation
-
Centre Hospitalier Universitaire DijonRecruiting
-
Jaeb Center for Health ResearchNational Eye Institute (NEI); Genentech, Inc.CompletedProliferative Diabetic RetinopathyUnited States
-
University of Sao Paulo General HospitalConselho Nacional de Desenvolvimento Científico e TecnológicoCompletedDiabetic Retinopathy
-
Federal University of São PauloUnknown
-
Baqiyatallah Medical Sciences UniversityCompletedDiabetes Mellitus, Type 2Iran, Islamic Republic of
-
Odense University HospitalUniversity of Southern Denmark; Velux FondenCompletedDiabetes | Proliferative Diabetic Retinopathy | PDRDenmark
-
Odense University HospitalMoorfields Eye Hospital NHS Foundation Trust; University of Southern Denmark; Yamagata University and other collaboratorsCompletedProliferative Diabetic RetinopathyDenmark
-
Hermann Eye CenterEyetech PharmaceuticalsCompletedDiabetic Retinopathy | Iris NeovascularizationUnited States
-
Association for Innovation and Biomedical Research...CompletedDiabetes Mellitus Type II | Diabetes Mellitus Type I | High Risk Proliferative Diabetic RetinopathyPortugal
-
Asociación para Evitar la Ceguera en MéxicoCompletedBruch Rupture | Choroidal DetachmentMexico